科伦药业跌2.03%，成交额4.12亿元，主力资金净流入447.40万元

Company Overview - Sichuan Kelun Pharmaceutical Co., Ltd. is located in Chengdu, Sichuan Province, and was established on May 29, 2002. It was listed on June 3, 2010. The company primarily engages in the development, production, and sales of large-volume intravenous solutions. The revenue composition is as follows: non-intravenous solutions 48.37%, intravenous solutions 41.28%, research projects 7.01%, and others 3.33% [1][2]. Financial Performance - For the first half of 2025, Kelun Pharmaceutical achieved operating revenue of 9.083 billion yuan, a year-on-year decrease of 23.20%. The net profit attributable to shareholders was 1.001 billion yuan, down 44.41% year-on-year [2]. - Since its A-share listing, Kelun Pharmaceutical has distributed a total of 6.697 billion yuan in dividends, with 3.386 billion yuan distributed over the past three years [3]. Stock Market Activity - On September 9, Kelun Pharmaceutical's stock price fell by 2.03%, closing at 39.19 yuan per share, with a trading volume of 412 million yuan and a turnover rate of 0.79%. The total market capitalization is 62.628 billion yuan [1]. - Year-to-date, the stock price has increased by 33.17%, with a decline of 1.88% over the last five trading days, a rise of 7.61% over the last 20 days, and an increase of 11.49% over the last 60 days [1]. Shareholder Information - As of June 30, 2025, the number of shareholders of Kelun Pharmaceutical was 34,200, an increase of 2.55% from the previous period. The average number of circulating shares per shareholder was 38,138, a decrease of 2.49% [2]. - The top ten circulating shareholders include notable funds such as China Europe Medical Health Mixed A and Hong Kong Central Clearing Limited, with varying changes in their holdings [3].